In accounting, IPR&D (in-process research and development) is an intangible asset recorded on an acquirer’s balance sheet after a business combination, representing the fair value of the target company’s unfinished research projects. A pharmaceutical buyer, for example, may pay billions largely for drug candidates still in clinical trials. Under U.S. GAAP, the acquirer must identify those incomplete projects, measure what each is worth at the acquisition date, and carry that value as a separate asset until the project either reaches completion or is abandoned.
How IPR&D Differs From a Company’s Own R&D Spending
The treatment of acquired IPR&D is the mirror image of how a company accounts for its own internal research. When a company spends money on its own R&D, those costs hit the income statement immediately. ASC 730 requires this because the future economic benefits of most research are too uncertain to justify recording an asset.1U.S. Securities and Exchange Commission. 7. Intangible Assets A pharmaceutical company might spend $2 billion a year developing its own drug pipeline and expense every dollar of it in the period incurred.
Acquired IPR&D flips that treatment. When the same company buys another firm whose drug candidates are mid-development, the fair value of those incomplete projects is capitalized as an intangible asset. The purchase price has to be allocated across everything of value that was acquired, and an unfinished project with commercial potential is something of value.
The reporting consequence is worth understanding. Two identical drug candidates at the same stage of development will look different on the books depending on how the company came to own them: the internally developed one is invisible on the balance sheet, and the acquired one sits there as an asset.
Getting IPR&D Onto the Balance Sheet
When one business acquires another, ASC 805 requires the acquirer to identify and measure every asset and liability of the target at fair value. This purchase price allocation distributes the total consideration paid across tangible assets, identifiable intangible assets like customer relationships and trade names, liabilities assumed, and goodwill.2Deloitte Accounting Research Tool. Deloitte Roadmap – Business Combinations – 4.10 Intangible Assets
IPR&D sits in the identifiable intangible category. To qualify, an incomplete project must either arise from contractual or legal rights or be separable from the business and capable of being sold on its own. It also has to have real substance and genuinely be unfinished. Projects that fail either test have their value absorbed into goodwill rather than standing as a separate asset.
That distinction between IPR&D and goodwill has real consequences downstream. Goodwill is never amortized under current GAAP; it sits on the balance sheet and is tested for impairment. IPR&D, by contrast, will eventually convert into an amortizing asset if the project succeeds or be written off entirely if it fails. Properly identifying IPR&D therefore pulls value out of the permanent goodwill bucket and into one that will directly affect future income.
How IPR&D Is Valued
Assigning a fair value to something that doesn’t yet exist as a finished product is inherently judgmental. IPR&D measurements almost always land in Level 3 of the ASC 820 fair value hierarchy, the category reserved for valuations that rely on unobservable inputs like projected cash flows, discount rates, and probability estimates rather than observable market prices.3U.S. Securities and Exchange Commission. The Fair Value Measurement Accounting Standard, Codified in ASC 820
The Income Approach
Valuation specialists overwhelmingly use an income-based approach, projecting the cash flows the project should generate after commercialization and discounting them back to present value. The most common technique is the Multi-Period Excess Earnings Method (MPEEM), which isolates the earnings attributable to the IPR&D asset by deducting charges for every other asset that contributes to those earnings, such as working capital, fixed assets, the assembled workforce, and existing technology.
Those deductions, called contributory asset charges, represent the fair return each supporting asset would earn if it were rented from a third party. In practice they can consume 30 to 60 percent of the gross earnings attributed to the project, so getting them right matters as much as the revenue forecast.
Discount Rates and Probability of Success
The discount rate applied to IPR&D cash flows runs meaningfully higher than a company’s overall weighted average cost of capital because it has to capture the technical, regulatory, and commercial risk of an unfinished project. A survey of biotech valuation professionals reported average discount rates of roughly 40 percent for early-stage projects, 27 percent for mid-stage, and 20 percent for late-stage assets. The earlier the project, the higher the rate.
The valuation also has to reflect a probability-of-success adjustment, quantifying the likelihood the project clears its remaining hurdles, whether a Phase III trial, FDA approval, or final engineering validation. Some valuators multiply projected cash flows by the probability of success; others build the probability into the discount rate. Whichever route is used, the two cannot both be applied, or risk gets double-counted.
Relief From Royalty
A secondary method, the Relief from Royalty approach, estimates value by calculating what the company would pay in royalties if it had to license the technology from a third party instead of owning it. The present value of those hypothetical royalty savings is treated as the asset’s fair value. It is less common for IPR&D and has drawn regulator scrutiny when it leans on generic industry royalty rates rather than deal-specific data.
Accounting Treatment After the Deal Closes
Once fair value is set, the acquirer records the IPR&D as an intangible asset and ASC 350-30 governs what happens next. The core rule: acquired IPR&D is classified as an indefinite-lived intangible asset and is not amortized while the underlying project remains in progress.4Deloitte Accounting Research Tool. 4.4 Intangible Assets Not Subject to Amortization
The logic is that no one knows how long the project will take or whether it will succeed at all. Setting an amortization schedule would require estimating a useful life, and that estimate would be meaningless for something that may never become a finished product. So the asset sits at its acquisition-date fair value, neither growing nor shrinking through amortization, until its fate is resolved.
This defers expense recognition. The acquirer has paid real consideration for the project, but the income statement won’t feel the impact until the project either succeeds (triggering amortization) or fails (triggering a write-off). In acquisition-heavy companies, billions of dollars in IPR&D can sit on the balance sheet for years.
Impairment Testing While the Project Is In Progress
Although IPR&D isn’t amortized, it isn’t left alone either. ASC 350-30-35-18 requires annual impairment testing, or more frequent testing whenever events suggest the asset may have lost value.4Deloitte Accounting Research Tool. 4.4 Intangible Assets Not Subject to Amortization Triggering events include failed clinical trials, a competitor reaching market first, regulatory setbacks, or shifts in the commercial landscape that undermine expected returns.
The test compares the asset’s fair value to its carrying amount. If carrying value exceeds fair value, the company records an impairment loss equal to the difference, and that loss flows through the income statement as a component of income from continuing operations. The adjusted carrying amount becomes the new baseline. Under GAAP, impairment losses are not reversed if circumstances later improve.
What Happens When the Project Resolves
Success
If the project reaches completion, typically marked by regulatory approval or the point where the product is ready for commercial use, the asset is reclassified from indefinite-lived to definite-lived. The company then assigns a useful life based on the expected period of economic benefit, often tied to remaining patent life or the anticipated product lifecycle, and begins systematic amortization.1U.S. Securities and Exchange Commission. 7. Intangible Assets That amortization reduces reported earnings each period across the asset’s useful life.
Failure
If the project is abandoned or it becomes clear the technology will never reach commercial viability, the entire remaining carrying value is written off in the period the decision is made. That produces a potentially large non-cash impairment charge. For companies that acquired multiple IPR&D projects in a single deal, one project’s failure can materially depress GAAP earnings for the quarter even though no cash leaves the business.
Watch how companies present these write-offs. Many exclude IPR&D impairment charges from non-GAAP earnings, presenting adjusted figures that strip out the loss. That is not inherently misleading, since the charge is non-cash and non-recurring, but GAAP earnings and the adjusted numbers management highlights can diverge sharply in the period of a write-off.
Tax Treatment Does Not Follow the Book Treatment
The accounting treatment and the federal income tax treatment of acquired IPR&D operate on entirely different tracks. Conflating them is a common mistake. For GAAP, IPR&D sits unamortized on the balance sheet until the project concludes. For federal income tax purposes, IPR&D acquired in a business combination is generally treated as a Section 197 intangible, subject to straight-line amortization over 15 years regardless of the project’s status.5Office of the Law Revision Counsel. 26 U.S. Code 197 – Amortization of Goodwill and Certain Other Intangibles
The 15-year tax amortization starts when the asset is acquired, not when the project is completed. That creates a book-tax timing difference that generates a deferred tax liability on the GAAP balance sheet: the company is getting tax deductions each year for the amortizing IPR&D, but no corresponding GAAP expense hits the income statement until the project succeeds or fails. Analysts tracking a company’s effective tax rate after a large acquisition should expect that divergence.
Why IPR&D Disclosures Deserve a Close Read
IPR&D valuations have drawn recurring SEC scrutiny because they lean almost entirely on management judgment about future cash flows, discount rates, and probability of success. A company motivated to minimize future amortization might undervalue IPR&D to push more of the purchase price into goodwill, which is never amortized.
SEC staff has flagged several recurring problems in IPR&D valuations: treating attributes of already-completed technology as though they belong to the in-process project, using generic industry royalty rates that don’t reflect deal-specific economics, and failing to give proper credit to existing products and core technologies when allocating projected cash flows.6U.S. Securities and Exchange Commission. Letters re 1998/99 Audit Risk Alerts The staff has stated that material misvaluations of IPR&D may require restatement of financial statements.
For anyone reviewing an acquisition disclosure, the IPR&D line item deserves more than a glance. Compare how much of the total purchase price landed in IPR&D versus goodwill and other identifiable intangibles. Look at the discount rates and probability assumptions disclosed in the footnotes. And remember that the asset will eventually hit the income statement one way or the other, as steady amortization over a useful life or as a sudden impairment charge that wipes out the entire balance.